title: Treatment of refractory chronic urticaria with tumor necrosis factor-alfa inhibitors.
authors.forename: Lindsay H
authors.initials: LH
authors.lastname: Wilson
authors.forename: Mark J
authors.initials: MJ
authors.lastname: Eliason
authors.forename: Kristin M
authors.initials: KM
authors.lastname: Leiferman
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Hull
authors.forename: Douglas L
authors.initials: DL
authors.lastname: Powell
mesh_terms: D000068879:Adalimumab; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D002908:Chronic Disease; D000068800:Etanercept; D005260:Female; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D014581:Urticaria / Q000188:drug therapy*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab; D000068879:Adalimumab; D000068800:Etanercept